NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Providence Health & Services
University of Texas Southwestern Medical Center
Replimune Inc.
Dana-Farber Cancer Institute
University of Kansas Medical Center
Dana-Farber Cancer Institute